Noa G. Holtzman

655 total citations
51 papers, 273 citations indexed

About

Noa G. Holtzman is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Noa G. Holtzman has authored 51 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 19 papers in Oncology and 14 papers in Genetics. Recurrent topics in Noa G. Holtzman's work include Hematopoietic Stem Cell Transplantation (20 papers), CAR-T cell therapy research (12 papers) and Acute Lymphoblastic Leukemia research (10 papers). Noa G. Holtzman is often cited by papers focused on Hematopoietic Stem Cell Transplantation (20 papers), CAR-T cell therapy research (12 papers) and Acute Lymphoblastic Leukemia research (10 papers). Noa G. Holtzman collaborates with scholars based in United States, Croatia and Switzerland. Noa G. Holtzman's co-authors include Ashkan Emadi, Aaron P. Rapoport, Saurabh Dahiya, Nancy M. Hardy, Steven Z. Pavletic, Jean A. Yared, Ali Bukhari, Firas El Chaer, Kathleen Ruehle and Mehmet H. Kocoglu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and British Journal of Haematology.

In The Last Decade

Noa G. Holtzman

47 papers receiving 273 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noa G. Holtzman United States 8 148 96 47 45 38 51 273
Lamis Eldjerou United States 10 178 1.2× 65 0.7× 55 1.2× 29 0.6× 38 1.0× 22 260
Vipul Sheth United States 7 184 1.2× 99 1.0× 84 1.8× 58 1.3× 44 1.2× 22 273
Eugenio Galli Italy 9 176 1.2× 46 0.5× 49 1.0× 37 0.8× 30 0.8× 43 280
Alessandro Crotta United States 7 273 1.8× 99 1.0× 55 1.2× 48 1.1× 26 0.7× 26 369
Sanbin Wang China 9 137 0.9× 102 1.1× 52 1.1× 74 1.6× 24 0.6× 31 259
Uri Greenbaum Israel 9 117 0.8× 37 0.4× 55 1.2× 37 0.8× 36 0.9× 26 232
Alberto Mussetti Spain 13 251 1.7× 196 2.0× 97 2.1× 96 2.1× 23 0.6× 51 435
Xiebing Bao China 10 89 0.6× 119 1.2× 42 0.9× 53 1.2× 10 0.3× 35 219
Carla Kreissig Germany 9 182 1.2× 105 1.1× 91 1.9× 106 2.4× 61 1.6× 11 369

Countries citing papers authored by Noa G. Holtzman

Since Specialization
Citations

This map shows the geographic impact of Noa G. Holtzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noa G. Holtzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noa G. Holtzman more than expected).

Fields of papers citing papers by Noa G. Holtzman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noa G. Holtzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noa G. Holtzman. The network helps show where Noa G. Holtzman may publish in the future.

Co-authorship network of co-authors of Noa G. Holtzman

This figure shows the co-authorship network connecting the top 25 collaborators of Noa G. Holtzman. A scholar is included among the top collaborators of Noa G. Holtzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noa G. Holtzman. Noa G. Holtzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiménez, Adriana, Mark Goodman, Lazaros J. Lekakis, et al.. (2026). Cytomegalovirus Lymphadenitis Mimicking Relapsed Lymphoma After CD19 Chimeric Antigen Receptor ( CAR ) T Cell Therapy. Apmis. 134(2). e70172–e70172.
2.
Dreyzin, Alexandra, Noa G. Holtzman, & Challice L. Bonifant. (2025). CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia. British Journal of Haematology. 207(4). 1178–1191. 1 indexed citations
3.
Holtzman, Noa G., Rachel B. Salit, Brian C. Shaffer, et al.. (2024). High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Advances. 8(16). 4294–4310. 4 indexed citations
4.
Anderson, Anthony D., Yoichiro Natori, Mohammed Raja, et al.. (2024). Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Advances. 8(14). 3813–3822. 12 indexed citations
5.
McManus, Taylor, Noa G. Holtzman, Susan Vitale, et al.. (2024). Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease. SHILAP Revista de lepidopterología. 5(1). 100627–100627. 1 indexed citations
6.
Holtzman, Noa G., Annie Im, Arlene Berman, et al.. (2023). Baricitinib for Refractory Chronic Graft-Versus-Host Disease (cGVHD): Results of a Phase 1/2 Study. Transplantation and Cellular Therapy. 29(2). S251–S252. 1 indexed citations
7.
Steinberg, Seth M., Noa G. Holtzman, Eduard Schulz, et al.. (2023). Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease. Bone Marrow Transplantation. 58(12). 1377–1383. 1 indexed citations
8.
Pang, Yifan & Noa G. Holtzman. (2023). Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia. Best Practice & Research Clinical Haematology. 36(2). 101475–101475. 1 indexed citations
9.
Steinberg, Seth M., Sandra A. Mitchell, Noa G. Holtzman, et al.. (2022). Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease. HemaSphere. 6(6). e730–e730. 1 indexed citations
10.
Holtzman, Noa G., Seth M. Steinberg, Edward W. Cowen, et al.. (2021). Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy. 27(11). 937.e1–937.e7. 4 indexed citations
11.
Holtzman, Noa G., Alison Duffy, Rima Koka, et al.. (2021). Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens. Cancer Chemotherapy and Pharmacology. 87(6). 817–826. 5 indexed citations
12.
Holtzman, Noa G., Hao Xie, Søren M. Bentzen, et al.. (2020). Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncology. 23(1). 112–121. 71 indexed citations
13.
Lutfi, Forat, Noa G. Holtzman, Ali Bukhari, et al.. (2020). Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma. British Journal of Haematology. 192(1). 212–216. 15 indexed citations
14.
15.
16.
Chaer, Firas El, Noa G. Holtzman, Edward A. Sausville, et al.. (2019). Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib. Acta Haematologica. 141(2). 107–110. 14 indexed citations
17.
Holtzman, Noa G., et al.. (2017). Promyelocytic sarcoma of the right humerus: an unusual clinical presentation with unique diagnostic and treatment considerations. Clinical Case Reports. 5(11). 1874–1877. 2 indexed citations
18.
19.
Chaer, Firas El, Noa G. Holtzman, Neil C. Porter, et al.. (2017). Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL. Bone Marrow Transplantation. 52(11). 1583–1584. 6 indexed citations
20.
Reddy, Haritha, Alison Duffy, Noa G. Holtzman, & Ashkan Emadi. (2016). The role of β-elimination for the clinical activity of hypomethylating agents and cyclophosphamide analogues.. PubMed. 3(1). 1–8. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lamis Eldjerou Breakdown of academic impact, for papers by Vipul Sheth Breakdown of academic impact, for papers by Eugenio Galli Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Sanbin Wang Breakdown of academic impact, for papers by Uri Greenbaum Breakdown of academic impact, for papers by Alberto Mussetti Breakdown of academic impact, for papers by Xiebing Bao Breakdown of academic impact, for papers by Carla Kreissig
Rankless by CCL
2026